Accessibility Menu
PolyNovo logo

PolyNovo(ASX) PNV

Market CapA$739.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1998)+435%
5 Year-52%
1 Year-5%
1 Month+13%
A$1.07
-3.60%
-0.04Today
PolyNovo last closing stock price
MetricPriceDate
Last closeAUD 1.072026-08-21
PolyNovo stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10.88%AUD 0.972026-08-14
1 month+12.63%AUD 0.952026-07-22
3 month-5.73%AUD 1.142026-05-22
Year to date-13.01%AUD 1.232025-12-31
1 year-4.89%AUD 1.132025-08-21
3 year-31.19%AUD 1.562023-08-22
5 year-52.23%AUD 2.242021-08-20
Since inception+435%AUD 0.201998-11-26

PolyNovo Financials at a Glance

Market Cap

A$739.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$253.51M

Net Income (TTM)

A$15.78M

EPS (TTM)

A$0.01

P/E Ratio

74.83

Dividend

A$0.00

Beta (Volatility)

0.27 (Low)

Price

A$1.07

Volume

1,904,071

Open

A$1.09

Previous Close

A$1.07

Daily Range

A$1.06 - A$1.10

52-Week Range

A$0.81 - A$1.67

Estimated Earnings Date

Mar 2, 2027

PNV News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PolyNovo

PolyNovo Limited is a medical device company specializing in biodegradable products designed for wound care and tissue regeneration. The company operates in multiple international markets, including Australia, the United States, and Europe, focusing on innovative solutions for complex medical challenges.

Products and Services
  • Offers NovoSorb Biodegradable Temporising Matrix for dermal regeneration
  • Developing hernia repair devices and solutions for abdominal wall reconstruction
  • Innovative products for chronic and surgical wound management
Growth Outlook
  • Recent quarterly revenue reached AUD 70.2 million, indicating strong demand
  • Gross profit margin improved to 30.6% in the latest quarter
  • Expansion into new markets is expected to drive future growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 246.5 million, reflecting consistent growth
  • Operating income margin of 2.8% in the latest quarter
  • Current ratio of 3.03, indicating strong liquidity position
PolyNovo Limited has established itself as a leader in the biodegradable medical device sector, with a focus on innovative solutions that address significant healthcare needs. The company's flagship product, the NovoSorb Biodegradable Temporising Matrix, is designed to facilitate dermal regeneration, making it a critical tool in the treatment of extensive surgical wounds, trauma, and burns. The growth outlook for PolyNovo appears promising, with recent quarterly revenue figures demonstrating robust demand for its products. The improvement in gross profit margins suggests effective cost management and operational efficiency. Furthermore, the company's strategic expansion into new markets is anticipated to bolster its revenue streams and enhance its competitive position. Financially, PolyNovo has shown resilience, with a trailing twelve months revenue of AUD 246.5 million. The operating income margin of 2.8% in the latest quarter reflects the company's ability to generate profit from its operations. Additionally, a current ratio of 3.03 indicates a strong liquidity position, providing the company with the flexibility to invest in growth opportunities and navigate potential challenges. Overall, PolyNovo Limited presents a compelling opportunity for investors interested in the healthcare sector, particularly in innovative medical devices that address critical patient needs.
AI Generated • Aug 21, 2026

Industry

Healthcare Equipment and Supplies

Employees

301

CEO

Robyn Elliott, PhD

Headquarters

Port Melbourne, VIC 3207, AU

PNV Financials

Key Financial Metrics (TTM)

Gross Margin

32.31%

Operating Margin

1.98%

Net Income Margin

7.16%

Return on Equity

11.87%

Return on Capital

4.47%

Return on Assets

8.01%

Earnings Yield

1.34%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$739.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

690.84M

Volume

1.90M

Avg. Volume

2.75M

Financials (TTM)

Gross Profit

A$117.40M

Operating Income

A$6.12M

EBITDA

A$16.24M

Operating Cash Flow

A$15.51M

Capital Expenditure

-A$26.49M

Free Cash Flow

-A$10.98M

Cash & ST Invst.

A$29.26M

Total Debt

A$31.74M

PolyNovo Performance Analysis

PolyNovo annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 41,439,839N/A
20232023-06-30AUD 65,241,46957.4%
20242024-06-30AUD 103,192,00058.2%
20252025-06-30AUD 127,243,00023.3%
PolyNovo sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3018.9%
Q22024-12-316.2%
Q42025-06-3013.8%
Q22025-12-313.7%
PolyNovo annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.00N/A
20232023-06-30AUD -0.01300.0%
20242024-06-30AUD 0.01N/A
20252025-06-30AUD 0.02154.7%
PolyNovo sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-5.1%
Q22024-12-3129.7%
Q42025-06-30197.9%
Q22025-12-31-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$70.20M

+48.9%

Gross Profit

A$21.46M

+29.3%

Gross Margin

30.57%

N/A

Market Cap

A$739.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.46M

N/A

Employees

301

N/A

Net Income

A$3.00K

-99.9%

EBITDA

A$3.36M

+34.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$29.26M

-35.9%

Total Debt

A$31.74M

+107.0%

Accounts Receivable

A$24.21M

+70.8%

Inventory

A$11.85M

+72.1%

Long Term Debt

A$28.94M

+111.3%

Short Term Debt

A$2.80M

+71.2%

Return on Assets

8.01%

N/A

Return on Invested Capital

2.72%

N/A

Free Cash Flow

-A$1.62M

-3408.2%

Operating Cash Flow

A$9.16M

+688.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMR.AXImricor Medical Systems, Inc.
A$2.01-1.95%
IDX.AXIntegral Diagnostics Limited
A$2.25-1.32%
OCA.AXOceania Healthcare Limited
A$0.68+0.75%
HLS.AXHealius Limited
A$0.46-2.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About PNV

What is the current price of PolyNovo?

PolyNovo is trading at A$1.07 per share.

What is the 52-week range for PolyNovo?

Over the past 52 weeks, PolyNovo has traded between A$0.81 and A$1.67.

How much debt does PolyNovo have?

As of the most recent reporting period, PolyNovo reported total debt of A$17.14M.

How much cash does PolyNovo have on hand?

PolyNovo reported A$33.53M in cash and cash equivalents in its most recent financial results.

What is PolyNovo’s dividend yield?

PolyNovo does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.